Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
Phase 1
35
about 4.3 years
50–85
2 sites in CA, RI
About this study
Researchers are testing a treatment called emtricitabine versus placebo in people with Alzheimer's disease, mild cognitive impairment, or moderate dementia. The trial will last about 12 months and involve taking either the drug or a placebo daily.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Emtriva Capsule
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
oral
Primary: Number of participants with treatment emergent adverse events (TEAE's) in the treatment group will be compared to the placebo group
Secondary: Change from baseline in Alzheimer's Disease Assessment Scale-cognitive (ADAS-Cog -13), Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), Change from baseline in Clinical Dementia Rating (CDR), Change from baseline in Free and Cued Selective Reminding Test (FCSRT+IR) with delayed recall, Change from baseline in cerebrospinal fluid (CSF) phosphorylated tau/amyloid beta 42 (pTau/Aβ42) ratios, Change from baseline in key inflammatory biomarkers; Tumor necrosis factor-alpha (TNF-α), Interleukin 1-beta (IL-1β), and Interferon-alpha (IFN-α), Change in Mini Mental State Examination (MMSE) Total Scores
Neurology